JBL— AI Stock Forecast & Price Targets

Revenue is re-accelerating: quarterly revenue climbed from $8.25B (Aug-25) to $8.75B (May-26), with Q/Q sales growth of 11.8% and Y/Y TTM sales +17.8% — a clear inflection driven by AI infrastructure and healthcare exposure. Gross margin held ~9.0-9.5% and operating margin recovered to 5.2% in the latest quarter, while net income of $275M was the strongest of the last four quarters. Cash flow is healthy: TTM FCF of $1.21B against $34B revenue, with the latest quarter delivering $351M FCF despite $184M capex tied to Marshall County-style expansion. The weak spots are the balance sheet and quality-of-equity metrics: stockholders' equity has actually shrunk to $1.32B while total debt sits at $3.89B (D/E 2.94), driving a headline ROE of 66% that is more leverage than operational excellence. Current ratio 0.98 and negative working capital of -$353M signal aggressive capital allocation (buybacks — the $902M program just completed) rather than a fortress balance sheet. Valuation is mixed: trailing P/E 40 is rich, but forward P/E 19.3 and PEG 0.71 look reasonable if EPS growth (next Y +31%, 5Y +27%) materializes.

Across timeframes the picture is a strong uptrend now digesting: the weekly chart shows a parabolic move from ~$100 to $428 peak with price now $321, the daily shows a break of near-term structure with a lower high around $340 and price sitting near prior support ~$320-325, the 4h shows a clear head-and-shoulders-like top with declining highs, and the 1h shows a capitulation low near $317 with a modest reflex bounce. RSI at 37, SMA20 -10.5%, SMA50 -10.1% place the stock in short-term oversold territory while SMA200 remains +18.8% (uptrend intact). The forecast bands are worth calling out but not obeying blindly: the 1h band projects a mean-reversion pop to ~$351, the 4h band bleeds to $293, the daily to $244, and the weekly to $125 — the latter two are extreme given a MAPE of 33-40% and directional accuracy that only matches the naive baseline. Key levels: support $317-320 (recent low) then $300 psychological; resistance $340 (broken shelf), $360-365 (short-term forecast cluster), then $385-390.

• AI infrastructure buildout — $119M+ dedicated datacenter infrastructure facility investment referenced in recent coverage supports the Intelligent Infrastructure segment.
• Marshall County facility expansion continues to add capacity for high-margin advanced computing and AI supercomputer platforms.
• Healthcare & regulated industries — medical device manufacturing scaling into a secular onshoring/reshoring tailwind.
• EPS estimate upgrades: next-year EPS growth raised from 18.6% → 25.9% → 31.0% over 45 days, indicating sell-side conviction is building.
• Just-completed $902M buyback signaling management confidence and providing per-share EPS support even at flat net income.

• Debt/Equity 2.94 with shrinking book equity — leverage-driven ROE is a red flag if margins soften.
• Longer-horizon forecast bands imply meaningful downside ($244 on daily, $125 on weekly) — even if MAPE is high, the directional signal is bearish.
• Current ratio 0.98 and negative working capital of -$353M leave little cushion if the AI capex cycle slows.
• Gross margin only 9% — a thin buffer; any input cost or pricing pressure flows straight through.
• Stock is up 45% YTD and 464% over 5 years — momentum crowding risk with 3.02% short float still modest, meaning limited squeeze support on further downside.
• Omnibus shelf registration creates dilution optionality that could be exercised if leverage becomes problematic.
• Extreme social/retail chatter (pump-style messages in the sentiment data) suggests some froth in the retail crowd.